Anixa Biosciences IncNASDAQ:ANIX
- LAST PRICE3.2200
- TODAY'S CHANGE (%)-0.0600 (-1.8293%)
- Bid / Lots3.1700/ 3
- Ask / Lots3.7200/ 3
- Open / Previous Close3.2800 / 3.2800
- Day Range
- 52 Week Range
- Volume43,516
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANIX |
|---|---|---|
| 09:32 ET | 449 | 3.45 |
| 09:34 ET | 5000 | 3.25 |
| 09:36 ET | 1031 | 3.27 |
| 09:38 ET | 3325 | 3.45 |
| 09:41 ET | 1400 | 3.37 |
| 09:43 ET | 125 | 3.44 |
| 09:45 ET | 100 | 3.44 |
| 09:48 ET | 1361 | 3.4 |
| 10:01 ET | 1464 | 3.37 |
| 10:15 ET | 100 | 3.3 |
| 10:17 ET | 1900 | 3.34 |
| 10:32 ET | 100 | 3.29 |
| 10:33 ET | 125 | 3.36 |
| 11:02 ET | 500 | 3.226 |
| 11:06 ET | 2197 | 3.1801 |
| 11:08 ET | 100 | 3.18 |
| 11:09 ET | 100 | 3.18 |
| 11:13 ET | 100 | 3.18 |
| 11:38 ET | 250 | 3.21 |
| 12:00 ET | 100 | 3.24 |
| 12:02 ET | 1037 | 3.3196 |
| 12:39 ET | 659 | 3.28 |
| 12:41 ET | 100 | 3.28 |
| 12:48 ET | 100 | 3.3099 |
| 12:59 ET | 1100 | 3.24 |
| 01:15 ET | 500 | 3.215 |
| 01:24 ET | 100 | 3.25 |
| 02:09 ET | 500 | 3.2105 |
| 02:11 ET | 1896 | 3.21 |
| 02:13 ET | 5000 | 3.21 |
| 02:15 ET | 148 | 3.21 |
| 02:26 ET | 645 | 3.21 |
| 02:40 ET | 100 | 3.18 |
| 02:42 ET | 200 | 3.2 |
| 02:44 ET | 894 | 3.21 |
| 02:45 ET | 100 | 3.21 |
| 02:56 ET | 200 | 3.225 |
| 03:23 ET | 125 | 3.29 |
| 03:41 ET | 100 | 3.28 |
| 03:43 ET | 152 | 3.27 |
| 03:48 ET | 200 | 3.26 |
| 03:52 ET | 856 | 3.2886 |
| 03:56 ET | 625 | 3.26 |
| 03:57 ET | 1100 | 3.24 |
| 03:59 ET | 300 | 3.22 |
May 22, 2023
BRIEF-Anixa Biosciences Announces Treatment Of Second Patient In Its Ovarian Cancer Car-T Clinical Trial, from 9:52AM ET on Monday May 22, 2023 by Thomson Reuters
9:52AM ET on Monday May 22, 2023 by Thomson ReutersAnixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial, from 8:30AM ET on Monday May 22, 2023 by PR Newswire
8:30AM ET on Monday May 22, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Anixa Biosciences Inc | 99.6M | -8.1x | --- |
Athira Pharma Inc | 99.8M | -1.0x | --- |
Adverum Biotechnologies Inc | 99.8M | -0.7x | --- |
Decibel Therapeutics Inc | 97.8M | -1.6x | --- |
Spruce Biosciences Inc | 96.6M | -1.3x | --- |
AN2 Therapeutics Inc | 103.3M | -2.1x | --- |
Company Information
Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others. Its vaccine programs include the development of a preventative vaccine against triple-negative breast cancer (TNBC), the lethal form of breast cancer, as well other forms of breast cancer, and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell (CAR- T) technology that is focused on treating ovarian cancer, which is developed at its subsidiary, Certainty Therapeutics, Inc., and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.
Contact Information
- Headquarters
- 3150 Almaden Expy Ste 250SAN JOSE, CA, United States 95118
- Phone
- 408-708-9808
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Amit Kumar
- President, Chief Financial Officer, Chief Operating Officer
- Michael Catelani
- Lead Independent Director
- Lewis Titterton
- Independent Director
- Arnold Baskies
- Independent Director
- Emily Gottschalk
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $99.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-0.40 |
Book Value | $0.94 |
P/E Ratio | -8.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
